OrexinReceptors (Hypocretin Receptor) Antagonist Market, by Application(Insomnia, Depression and Anxiety), by Dosage (5mg, 10mg, 15mg, and 20mg), andby Region (North America, Latin America, Europe, Asia Pacific, Middle East, andAfrica) - Size, Share, Outlook, and Opportunity Analysis, 2018 – 2026
Orexin (hypocretin) is aneuropeptide produced by the lateral hypothalamus which regulates thewakefulness, appetite, arousal and other habits. Orexin receptor antagonist isthe new class of drugs are used in the treatment of insomnia.
Suvorexant, is a dual orexinreceptor antagonist drug that blocks both pathways of OX1R and OX2R. Itdevelops sleep by the binding inhibition of orexin A and B, neuropeptides thatpromote wakefulness. Approximately 70,000 orexin neurons are present in thehuman brain, located in the perifornical lateral hypothalamus, which sendsignals throughout the brain and spinal cord.
Global Orexin ReceptorsAntagonist Market Drivers
The main growth driver for theOrexin receptors antagonist market is the rising cases of insomnia. Insomnia iscaused by plenty of reasons such as anxiety, stress and depression. Lifestyleproblems can trigger insomnia like irregular sleeping patters, drinking alcoholand smoking tobacco products before going to bed. Rising geriatric population,increased stress levels in urban population also results into insomnia.According to American Academy of Sleep Medicine AASM) as reported in 2014 insomnia affects 30% of adults, 15-20% haveshort term insomnia and 10% of adults have chronic insomnia worldwide.
* The sample copy includes: Report Summary, Table ofContents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copyof this report: https://www.coherentmarketinsights.com/insight/request-sample/2522
Growing awareness about insomniaand penetration of Belsomra into the market is expected to create more demandin ORA market. Moreover, studies arebeing conducted whether suvorexant can be used to treat depression and anxietyso that the ORA market can witness further growth.
Global Orexin ReceptorsAntagonist Market Restraints
Though suvorexant (OrexinReceptors Antagonist) is the best drug available against insomnia, otherclasses of drugs such as Benzodiazepines, Non-benzodiazepines, Antidepressants,Melatonin Antagonist and medical devices like 2Breathe Sleep Inducer, Sleep ShepherdBlue, Dreem Headband, Fisher Wallace Stimulator, SR1 Delta Sleeper can also beused to treat insomnia which can negatively impede the market growth. Moreover,in National Sleep Foundation (NSF) stated that in the year 2010 only 15% ofpeople were diagnosed with insomnia and only 6% receive the treatment for thesame. General negligence among the people about insomnia and the side effectsof drugs such as headache, sleepiness, next day drowsiness, weight lossrestricts the patients from using this medication.
Furthermore, clinical studies byNCBI in 2015 showed the placebo treatment for insomnia is also effective forthe patients which hampers the growth of ORA market.
Global Orexin Receptors AntagonistMarket Regional analysis
North America is leading theOrexin receptors antagonist market. Rising demand for insomnia treatment in theU.S. and Canada coupled with increase in awareness, and high healthcarespending are anticipated to drive the market.
Browse ResearchReport: https://www.coherentmarketinsights.com/ongoing-insight/orexin-receptors-hypocretin-receptor-antagonist-market-2522
Moreover, high prevalence ofinsomnia among geriatric population in the U.S. are expected to increase thedemand. According to AASM in 2017 30-50% population of U.S. over the age of 60has developed insomnia.
In Asia Pacific, China isexpected to show lucrative growth in the market owing to high prevalence ofinsomnia. According to China National Knowledge Interne (CNKI) in 2017 15% ofChina’s population is suffering from insomnia aging 43 and above From theJournal of Community Medicine & Health Education as reported in 2017 inIndia 72% of population above the age of 60 has insomnia. Asia Pacific isanticipated to witness significant growth in near future because of shift-workdisorder and increasing stress level is expected to increase the number ofpaitents in Asia Pacific. In addition, favorable reimbursement policies fortherapeutic products, strong product pipeline, and rising stress level areother reasons contributing to the growth.
Global Orexin ReceptorsAntagonist Market Key Players
Key competitors in the globalOrexin receptors antagonist market include Merck & Co. Inc., Sanofi,Pfizer, Inc., Takeda Pharmaceutical Company Ltd., Purdue Pharmaceuticals L.P.,Eisai, Co. Ltd., Meda Consumer Healthcare Inc., Pernix Therapeutics, VandaPharmaceuticals, and ECR Pharmaceuticals.
Buy-Now this researchreport: https://www.coherentmarketinsights.com/insight/buy-now/2522
AboutCoherent Market Insights:
CoherentMarket Insights is a prominent market research and consulting firm offeringaction-ready syndicated research reports, custom market analysis, consultingservices, and competitive analysis through various recommendations related toemerging market trends, technologies, and potential absolute dollaropportunity.
ContactUs:
mailto:sales@coherentmarketinsights.com
U.S.Office:
Name: Mr. Shah
CoherentMarket Insights 1001 4th Ave,
# 3200Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
